Loading...
OTCM
ADXS
Market cap1mUSD
Mar 10, Last price  
0.03USD
1D
0.00%
1Q
11.11%
Jan 2017
-99.97%
IPO
-100.00%
Name

Ayala Pharmaceuticals Inc

Chart & Performance

D1W1MN
OTCM:ADXS chart
No data to show
P/E
—
P/S
98.38
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.87%
Rev. gr., 5y
-70.74%
Revenues
13k
-94.80%
116,406552,868431,961154,20165,73629,690508,4810001,000,00003,994,85612,031,0506,063,0002,334,000253,0003,240,000250,00013,000
Net income
-48m
L+234.79%
-538,076-1,805,789-6,197,744-2,454,453-5,416,418929,244-10,812,200-8,115,740-12,069,687-19,986,826-16,525,314-47,031,118-73,556,230-93,435,402-66,515,000-17,792,000-26,469,000-17,862,000-14,359,000-48,072,000
CFO
-29m
L+92.91%
-436,636-1,539,930-1,795,045-4,234,046-4,153,088-2,034,636-6,423,940-8,942,842-4,568,344-8,713,945-17,021,659-24,135,544-9,070,545-76,923,985-62,129,000-14,950,000-21,940,000-15,439,000-15,284,000-29,485,000
Earnings
Apr 14, 2025

Profile

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
URL
https://ayalapharma.com/
IPO date
Jul 28, 2005
Employees
14
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑102021‑102020‑102019‑102018‑102017‑102016‑102015‑10
Income
Revenues
13
-94.80%
250
-92.28%
Cost of revenue
36,279
17,191
Unusual Expense (Income)
NOPBT
(36,266)
(16,941)
NOPBT Margin
Operating Taxes
(3,912)
50
Tax Rate
NOPAT
(32,354)
(16,991)
Net income
(48,072)
234.79%
(14,359)
-19.61%
Dividends
Dividend yield
Proceeds from repurchase of equity
20,001
(938)
BB yield
-498.19%
27.73%
Debt
Debt current
166
12
Long-term debt
8,325
3,083
Deferred revenue
Other long-term liabilities
7,828
1,335
Net debt
3,609
(22,113)
Cash flow
Cash from operating activities
(29,485)
(15,284)
CAPEX
(201)
Cash from investing activities
5,946
(166)
Cash from financing activities
26,001
(956)
FCF
(19,224)
(16,883)
Balance
Cash
4,882
25,208
Long term investments
Excess cash
4,881
25,196
Stockholders' equity
(197,214)
(442,957)
Invested Capital
195,017
466,596
ROIC
ROCE
1,650.71%
EV
Common stock shares outstanding
6,019
1,819
Price
0.67
-64.14%
1.86
283.82%
Market cap
4,015
18.68%
3,383
332.58%
EV
7,624
(18,730)
EBITDA
(35,897)
(16,627)
EV/EBITDA
1.13
Interest
15,746
Interest/NOPBT